Page last updated: 2024-12-06
2,3-Dimethylpyrazine
Description
2,3-Dimethylpyrazine is a heterocyclic compound with a characteristic roasted and nutty aroma. It is found naturally in roasted coffee beans, roasted peanuts, and other roasted foods. 2,3-Dimethylpyrazine is synthesized through a variety of methods, including the reaction of 2-methylpyrazine with methyl iodide or the reaction of 2,3-dichloropyrazine with methyl magnesium bromide. It is used as a flavoring agent in food and beverages and is also used as a fragrance component. The compound is studied for its potential health benefits, including its antioxidant and anti-inflammatory properties. 2,3-Dimethylpyrazine has been shown to inhibit the growth of certain cancer cells and to protect against oxidative stress. It is also studied for its potential to enhance cognitive function.'
2,3-dimethylpyrazine: an odorant that stimulates Grueneberg ganglion neurons; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 22201 |
| CHEMBL ID | 96425 |
| CHEBI ID | 193606 |
| SCHEMBL ID | 151026 |
| SCHEMBL ID | 19919479 |
Synonyms (41)
| Synonym |
|---|
| 2,3-dimethyl-pyrazine |
| CHEMBL96425 |
| 2,3-dimethylpyrazine |
| pyrazine, 2,3-dimethyl- |
| fema no. 3271 |
| ccris 2928 |
| 2,3-dimethyl-1,4-diazine |
| 2,3-dimethylpyrazine (natural) |
| einecs 227-630-0 |
| inchi=1/c6h8n2/c1-5-6(2)8-4-3-7-5/h3-4h,1-2h |
| 2,3-dimethylpyrazine, >=95%, fcc, fg |
| 2,3-dimethylpyrazine, 99% |
| 5910-89-4 |
| D1525 |
| CHEBI:193606 |
| A832162 |
| AKOS007930710 |
| unii-whf7883d0v |
| whf7883d0v , |
| FT-0609727 |
| 25704-73-8 |
| pyrazine, dimethyl- |
| S12348 |
| 2,3-dimethylpyrazine [fhfi] |
| 2,3-dimethylpyrazine [fcc] |
| SCHEMBL151026 |
| dimethylpyrazine |
| 2,3-dimethyl pyrazine |
| DTXSID4064058 |
| AM87085 |
| mfcd00006144 |
| 2,3-dimethylpyrazine, analytical reference material |
| fema 3271 |
| 2,3-dimethlpyrazine |
| SCHEMBL19919479 |
| AS-14037 |
| Q27292638 |
| CS-W016630 |
| EN300-44307 |
| HY-W015914 |
| Z448248230 |
Drug Classes (1)
| Class | Description |
|---|
| pyrazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 38.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 38.04 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 5.33 (4.65) | | Search Engine Demand Index | 46.50 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |